Skip to main content
. 2022 Feb 15;14(4):956. doi: 10.3390/cancers14040956
HCL classic hairy cell leukemia
Pas purine analogues
PFS progression-free survival
ORR overall response rate
CR complete remission
PR partial remission
MRD minimal residual disease
Moxe moxetumumab pasudotox
BTK Bruton’s tyrosine kinase
CAR chimeric antigen receptor-engineered